VISN 5 MIRECC - General Publications 2011
About Us • Clinical • Education • Research
VISN 5 MIRECC home
Brown, C.H., Bennett, M.E., Li, L., & Bellack, A.S. (2011). Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addictive Behaviors, 36(5), 439-437.
Brown, C.H., Medoff, D., Dickerson, F.B., Kreyenbuhl, J.A., Goldberg, R.W., Fang, L., & Dixon, L. (2011). Glucose control over time among type 2 diabetes patients with and without serious mental illness. Journal of Nervous and Mental Disease, 199(11), 899-902.
Buchanan, R.W., Keefe, R.S., Lieberman, J.A., Barch, D.M., Csernansky, J.G., Goff, D.C., Gold, J.M., Green, M.F., Jarskog, L.F., Javitt, D.C., Kimhy, D., Kraus, M.S., McEvoy, J.P., Mesholam Gately, R.I., Seidman, L.J., Ball, M.P., McMahon, R.P., Kern, R.S., Robinson, J., & Marder, S.R. (2011). A randomized clinical trial of MK -0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry, 69(5), 442-449.
Carpenter, W.T. (2011). Criticism of the DSM-V risk syndrome: A rebuttal. Cognitive Neuropsychiatry, 16(2), 101-106.
Carpenter, W.T. (2011). The facts of schizophrenia: A personal commentary. Schizophrenia Research, 128(1-3), 3-4.
Carpenter, W.T. (2011). One hundred years. Schizophrenia Bulletin, 37(3), 443-444.
Carpenter, W.T., & van Os, J. (2011). Should attenuated psychosis syndrome be a DSM-5 diagnosis? American Journal of Psychiatry, 168, 460-463.
Carter, C.S., Barch, D.M., Bullmore, E., Breiling, J., Buchanan, R.W., Butler, P., Cohen, J.D., Geyer, M., Gollub, R., Green, M.F., Jaeger, J., Krystal, J.H., Moore, H., Nuechterlein, K., Robbins, T., Silverstein, S., Smith, E.E., Strauss, M., & Wykes, T. (2011). Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biological Psychiatry, 70(1), 7-12.
Couture, S.M., Blanchard, J.J., & Bennett, M.E. (2011). Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia. Psychiatry Research, 189(1), 43-48.
Day, H.R., Morgan, D.J., Young, A., Himelhoch, S., & Perencevich, E.N. (2011). Association between depression and contact precautions in veterans at hospital admission. American Journal of Infection Control, 39(2), 163-5.
Day, H.R., Perencevich, E.N., Harris, A.D., Gruber-Baldini, A.L., Himelhoch, S., Brown, C.H., Dotter, E., & Morgan, D.J. (2011). The association between contact precautions and delirium at a tertiary care center. Infection Control and Hospital Epidemiology, 33, 34-9.
Day, H.R., Perencevich, E.N., Harris, A.D., Himelhoch, S.S., Brown, C.H., Gruber-Baldini, A.L., Dotter, E., & Morgan, D.J. (2011). Do contact precautions cause depression? A two-year study at a tertiary care medical centre. Journal of Hospital Infection, 79(2), 103-107.
Dickerson, F., Bennett, M., Dixon, L., Burke, E., Vaughan, C., Delahanty, J., & DiClemente, C. (2011). Smoking cessation in persons with serious mental illness: The experience of successful quitters. Psychiatric Rehabilitation Journal, 34(4), 311-316.
DiClemente, C.C., Delahanty, J.C., Kofeldt, M.G., Dixon, L., Goldberg, R., & Lucksted, A. (2011). Stage movement following a 5A’s intervention in tobacco dependent individuals with serious mental illness (SMI). Addictive Behavior, 36(3), 261-264.
Divilbiss, M., McCleery, A., Aakre, J.M., Seghers, J.P., Schumann, E.B., & Docherty, N.M. (2011). Reality monitoring and its association with social functioning in schizophrenia. Psychiatry Research 186(1), 1-4.
Dixon, L., Lewis-Fernandez, R., Goldman, H.H., Interian, A., Michaels, A., & Kiley, M.C. (2011). Adherence disparities in mental health: Opportunities and challenges. Journal of Nervous and Mental Disease, 199(10), 815-820.
Dixon, L.B., Lucksted, A., Medoff, D., Burland, J., Stewart, B., Lehman, A., Fang, L., Sturm, V., Brown, C., & Murray-Swank, A. (2011). Outcomes of a randomized study of a peer-taught Family-To-Family education program for mental illness. Psychiatric Services, 62, 591-597.
Docherty, N.M., St-Hilaire, A., Aakre, J.M., Seghers, J.P., McCleery, A., & Divilbiss, M. (2011). Anxiety interacts with expressed emotion criticism in the prediction of psychotic symptom exacerbation. Schizophrenia Bulletin, 37(3), 611-618.
Drapalski, A. L., Bennett, M., & Bellack, A. S. (2011). Gender differences in substance use, consequences, motivation to change, and treatment seeking in people with serious mental illness. Substance Use & Misuse, 46(6), 808-818.
Drapalski, A.L., & Dixon, L.B. (2011). Programmes to support family members and carers. In G. Thornicroft, G. Szmukler, K. Mueser, & R. Drake (Eds.), Oxford Textbook of Community Mental Health, 2nd Edition. Oxford: Oxford University Press.
Ehrenreich, B., Righter, B., Rocke, D., Dixon, L., & Himelhoch, S. (2011). Are mobile phones and handheld computers being used to enhance delivery of psychiatric treatment? A systematic review. Journal of Nervous and Mental Disease, 199 (11), 886-891.
Essock, S.M., Schooler, N.R., Stroup, T.S., McEvoy, J.P., Rojas, I., Jackson, C., Covell, N.H., Schizophrenia Trials Network. (2011). Effectiveness of switching from polypharmacy to monotherapy. American Journal of Psychiatry, 168(7), 702-708.
Fischer, BA, & Buchanan, RW. (2011). Schizophrenia: Clinical manifestations, assessment, diagnosis, and course. In: D.S. Basow (Ed.), UpToDate. Waltham, MA: UpToDate.
Forbes, C.B., Blanchard, J.J., Bennett, M., Horan, W.P., Kring, A., & Gur, R. (2010). Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms. Schizophrenia Research, 124, 36-42.
Green, M.F., Schooler, N.R., Kern, R.S., Frese, F.J., Granberry, W., Harvey, P.D., Karson, C.N., Peters, N., Stewart, M., Seidman, L.J., Sonnenberg, J., Stone, W.S., Walling, D., Stover, E., & Marder, SR. (2011). Evaluation of co-Primary measures for clinical trials of cognition enhancement in schizophrenia. American Journal of Psychiatry, 168, 400-407.
Himelhoch, S., Goldberg, R., Calmes, C., Medoff, D., Slade, E., Gallucci, G., Dixon, L., & Rosenberg, S. (2011). Screening for and prevalence of HIV and hepatitis C among an outpatient urban sample of people with serious mental illness and co occurring substance abuse. Journal of Community Psychology, 39(2), 231-239.
Himelhoch, S., Mohr, D., Weber, E., Maxfield, J., Clayton, S., Medoff, D., & Dixon, L. (2011). Feasibility of telephone based cognitive behavioral therapy targeting major depression among urban dwelling African-Americans with co-occurring HIV. Psychology, Health & Medicine, 16(2), 156-165.
Hong, L.E., Schroeder, M., Ross, T.J., Buchholz, B., Salmeron, B.J., Wonodi, I., Thaker, G.K., & Stein E.A. (2011). Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophrenia Bulletin, 37(2), 416-25.
Hong, L.E., Thaker, G.K., McMahon, R.P., Summerfelt, A., Rachbeisel, J., Fuller, R.L., Wonodi, I., Buchanan, R.W., Myers, C., Heishman, S.J., Yang, J, & Nye, A. (2011). Effects of moderate-dose treatment with varenicline on neuro-biological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 68(12), 1195-1206.
Hong, L.E., Yang, X., Wonodi, I., Hodgkinson, C.A., Goldman, D., Stine, O.C., Stein, E.S., & Thaker, G.K. (2011). A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes, Brain, & Behavior, 10(5), 530-535.
Hou, Y.Z., Xiang, Y.T., Yan, F., Ungvari, G.S., Dickerson, F., Chiu, H.F.K., Lai, K.Y.C., Lee, E.H.M., Li, W.Y., Li, W.X., Zhu, Y.L., & Dixon, L.B. (2011). Cigarette smoking in community-dwelling patients with schizophrenia in China. Journal of Psychiatric Research, 45 (12), 1551-1556.
Keshavan, M.S., Morris, D.W., Sweeney, J.A., Pearlson, G., Thaker, G., Seidman, L.J., Eack, S.M., & Tamminga, C. (2011). A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: The Schizo-Bipolar scale. Schizophrenia Research, 133 (1-3), 250-254.
Kirkpatrick, B., Strauss, G., Nguyen, L., Fischer, B.A., Daniel, D.G., Cienfuegos, A., Marder, S.R. (2011). The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin, 37(2), 300-305.
Kreyenbuhl, J., Leith, J, Medoff, D.R., Fang, L., Dickerson, F.B., Brown, C., Goldberg, R.W., Potts, W., & Dixon, L.B. (2011). A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Research, 188, 109-114.
Kreyenbuhl, J., Slade, E.P., Medoff, D.R., Brown, C.H., Ehrenreich, B., Afful, J., & Dixon, L.B. (2011). Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Research, 131(1-3), 127-132.
Lewis, R., Adler, D.A., Dixon, L.B., Goldman, B., Hackman, A.L., Oslin, D.W., Siris, S.G., & Valenstein, M. (2011). The psychiatric note in the era of electronic communication. Journal of Nervous and Mental Disease, 199(4), 212-13.
Lucksted, A., Drapalski, A.L., Calmes, C., Forbes, C., DeForge, B., & Boyd, J. (2011). Ending Self Stigma: Pilot evaluation of a new intervention to reduce internalized stigma among people with serious mental illnesses. Psychiatric Rehabilitation Journal, 35(1), 51-54.
Mann-Wrobel, M., Bennett, M.E., Weiner, E. E., Buchanan, R. W., & Ball, M.P. (2011). Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. Schizophrenia Research, 126(1-3), 277-283.
Nossell, I., Calmes, C., Brown, C., Kreyenbuhl, J., Goldberg, R., Fang, L., & Dixon, L. (2010). Patterns of emergency room use for medical conditions among those with serious mental illness. Psychiatric Services, 61, 1251-1254.
Weiner, E., Buchholz, A., Coffay, A., Liu, F., McMahon, R.P., Buchanan, R.W., & Kelly, D.L. (2011). Varenicline for smoking cessation in people with schizophrenia: A double blind randomized clinical trial. Schizophrenia Research, 129(1),94-95.
Weiner, E., Conley, R.R., Ball, M.P., Feldman, S., Gold, J.M., Kelly, D.L., Wonodi, I., McMahon, R.P., & Buchanan, R.W. (2010). Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology, 35(11), 2274-83.
Wonodi, I., Gopinath, H.V., Liu, J., Adami, H., Hong, L.E., Allen-Emerson, R., McMahon, R.P., & Thaker, G.K. (2011). Dipyridomole monotherapy in schizophrenia: Pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmocology, 218(2), 341-345.
Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., Kajii, Y., Thaker, G.K., & Schwarcz, R. (2011). Down-regulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Archives of General Psychiatry, 68(7), 665-674.
Xiang, Y.T., Wang, C.Y., Si, T.M., Lee, E.H., He, Y.L., Ungvari, G.S., Chiu, H.F., Shinfuku, N., Yang, S.Y., Chong, M.Y., Kua, E.H., Fujii, S., Sim, K., Yong, M.K., Trivedi, J.K., Chung, E.K., Udomratn, P., Chee, K.Y., Sartorius, N., Dixon, L.B., Kreyenbuhl, J.A., & Tan, C.H. (2011). Clozapine use in schizophrenia: Findings of the research on Asia psychotropic prescription (REAP) studies from 2001 to 2009. Australian and New Zealand Journal of Psychiatry, 45(11), 968-975.
Xiang, Y.T., Wang, C.Y., Ungvari, G.S., Kreyenbuhl, J.A., Chiu, H., Lai, K., Edwin Ho Ming Lee, B.O.Q.J., & Dixon, L.B. (2011). Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment in schizophrenia. Pharmacopsychiatry, 44(4), 135-141.
Young, A.S., Niv, N., Chinman, M., Dixon, L., Eisen, S.V., Fischer, E.P., Smith, J., Valenstein, M., Marder, S.R., & Owen, R.R. (2011). Routine outcomes monitoring to support improving care for schizophrenia: Report from the VA Mental Health QUERI. Community Mental Health Journal, 47(2), 123-35.
